A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 401–500 of 831
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
“A splice variant (rs72613567:TA) in HSD17B13, identified in the DiscovEHR study, was associated with reduced ALT/AST levels and improved liver histology in NASH, offering protection against NASH and cirrhosis [243,244].”
Fromme, M., Klebingat, F., Ellis, P., & Strnad, P. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000699 · Cited by 23
“[83] Risk factors for the development of liver fibrosis were found to be the same as in other AATD genotypes: male sex, presence of obesity, and age ≥ 50 years.”
Exploring the genetic basis of fatty liver development in geese
Yang, Y., Wang, H., Li, G., Liu, Y., Wang, C., & He, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-71210-8 · Cited by 39
Self-citationKalinowski, P., Smyk, W., Nowosad, M., Paluszkiewicz, R., Michałowski, Ł., Ziarkiewicz‐Wróblewska, B., Weber, S. N., Milkiewicz, P., Lammert, F., Zieniewicz, K., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415825 · Cited by 18
“[11] analyzed exome sequence data and electronic health records from participants in the DiscovEHR human genetics study as well as 2391 human liver biopsies and demonstrated that in homozygous and heterozygous carriers of the HSD17B13 variant, the risks of NAFLD and NASH-cirrhosis were reduced by 30% and 17%, and 49%…”
BackgroundMethodSun, D., Wang, T.-Y., Zheng, K. I., Zhang, H., Wang, X., Targher, G., Byrne, C. D., Chen, Y., Yuan, W., Jin, Y. J., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.018 · Cited by 18
“Currently, a significant association between the HSD17B13 rs72612567 variant and NAFLD has been reported only in Caucasian individuals [13, 30, 31].”
BackgroundLiver disease with unknown etiology – have you ruled out alpha-1 antitrypsin deficiency?
Patel, D. R., & Teckman, J. H. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622321995684 · Cited by 25
Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
Parameswaran, M., Hasan, H. A., Sadeque, J., Jhaveri, S., Avanthika, C., Arisoyin, A. E., Dhanani, M., & Rath, S. M. (2021) · Cureus · doi:10.7759/cureus.20776 · Cited by 22
“inflammation Decreases progression [97]”
Gellert‐Kristensen, H., Tybjærg‐Hansen, A., Nordestgaard, B. G., Ghouse, J., Fuchs, A., Kühl, J. T., Sigvardsen, P. E., Kofoed, K. F., & Stender, S. (2023) · Liver International · doi:10.1111/liv.15629 · Cited by 23
Self-citationMancina, R. M., Ferri, F., Farcomeni, A., Molinaro, A., Maffongelli, A., Mischitelli, M., Poli, E., Parlati, L., Burza, M. A., Santis, A. D., et al. (2019) · The Application of Clinical Genetics · doi:10.2147/tacg.s187922 · Cited by 17
“Additionally, very recently a loss-of-function variant in HSD17B13 (rs72613567) was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.(53) The inclusion of this protective variant in the risk score could improve the performance of similar risk scores in the fu…”
BackgroundDivergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse
Šmagris, Ē., Shihanian, L. M., Mintah, I. J., Bigdelou, P., Livson, Y., Brown, H. M., Verweij, N., Hunt, C., Johnson, R. O., Greer, T., et al. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011179 · Cited by 18
Self-citationKubina, M., Prasitsumrit, V., Tan, J., Quek, J. W. E., Peddu, D. K., Mishra, A. K., Danpanichkul, P., Mann, J. P., Trépo, E., Buch, S., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70256 · Cited by 22
STE20-type kinase TAOK3 regulates hepatic lipid partitioning
Xia, Y., Caputo, M., Cansby, E., Anand, S. K., Sütt, S., Henricsson, M., Porosk, R., Marschall, H., Blüher, M., & Mahlapuu, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101353 · Cited by 17
“Notably, among genetic variants that confer susceptibility to NAFLD, the best characterized are a single-nucleotide polymorphism in the PNPLA3 gene and a splice variant (rs72613567:TA) in the HSD17B13 gene, both of which encode proteins anchored to the liver lipid droplets [7,8].”
BackgroundAssociation of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis
Tang, S., Zhang, J., Mei, T., Zhang, W., Zheng, S.-J., & Yu, H. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-02067-y · Cited by 16
“N 2018[13] NAFLD Europe 210 - case control study TaqMan 46 374”
BackgroundInfluentialLoss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity
Zhang, Z., Xun, Y., Rong, S., Yan, L., SoRelle, J. A., Li, X., Tang, M., Keller, K., Ludwig, S. M., Moresco, E. M. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31812-4 · Cited by 20
Ajmera, V. H., Wang, N., Xu, H., Liu, C., & Long, M. T. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17452 · Cited by 18
Conway, J. R., Pouryahya, M., Gindin, Y., Pan, D. Z., Carrasco‐Zevallos, O. M., Mountain, V., Subramanian, G. M., Montalto, M., Resnick, M. B., Beck, A. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101016 · Cited by 20
“To better understand the etiology of NASH, genome-wide association studies (GWASs) studies have identified genetic risk factors associated with higher likelihood of NASH and progressive disease.(4,5) The clinical consequence of these at-risk single-nucleotide polymorphisms (SNPs) is best illustrated by PNPLA3 (rs73840…”
BackgroundTian, Y., & Wang, B. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16330 · Cited by 21
“55,56 To decipher the mechanisms underlying its protective role against fi brosis, studies have focused on examining its enzyme activity and identifying substrates.”
BackgroundInfluentialStudy on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis
Luo, K., Chen, Y., Fang, S., Wang, S., Wu, Z., & Li, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1231520 · Cited by 18
Protective alleles and precision healthcare in crewed spaceflight
Rutter, L. A., MacKay, M. J., Cope, H., Szewczyk, N. J., Kim, J., Overbey, E. G., Tierney, B. T., Muratani, M., Lamm, B., Bezdan, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49423-6 · Cited by 18
“3 (the rs72613567 variant of the HSD17B13 gene) in an allele and dose-dependent manner 113 .”
BackgroundJiao, S., Ren, Q., Chen, L., Zhou, Z., Cai, Z., Huang, W., Wang, B., Chen, S., Wang, W., Cao, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02720 · Cited by 18
Stokman, G., van den Hoek, A. M., Thorbek, D. D., Pieterman, E. J., Veidal, S. S., Basta, B. N., Iruarrizaga‐Lejarreta, M., van der Hoorn, J. W., Verschuren, L., Berbée, J. F. P., et al. (2020) · Liver International · doi:10.1111/liv.14643 · Cited by 18
Janik, M. K., Smyk, W., Kruk, B., Szczepankiewicz, B., Górnicka, B., Lebiedzińska, M., Potes, Y., Simões, I. C. M., Weber, S. N., Lammert, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03521-3 · Cited by 20
Pennisi, G., Pipitone, R. M., Enea, M., Vincentis, A. D., Battaglia, S. L., Marco, V. D., Martino, V. D., Spatola, F., Tavaglione, F., Gentilucci, U. V., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1877 · Cited by 17
Lin, Y., Liao, F., Chao, H., Chen, A., Jeng, Y., Lin, C., Tiao, M., Yang, Y., Yeung, C., Chen, H., et al. (2025) · JGH Open · doi:10.1002/jgh3.70137 · Cited by 20
“A common loss- of-function variant of HSD17B13 (rs72613567: TA) protects patients against MASLD [53].”
Using Human Genetics to Drive Drug Discovery: A Perspective
Fox, C. S. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.12.045 · Cited by 16
Urias, E., Tedesco, N. R., Burkholder, D. A., Moran, I. J., Miller, M. J., Jasty, V. S. J., Patil, S. B., Zoellner, S., Wijarnpreecha, K., & Chen, V. L. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000441 · Cited by 18
Wajsbrot, N. B., Leite, N. C., Salles, G. F., & Villela‐Nogueira, C. A. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2890 · Cited by 17
Balcar, L., Scheiner, B., Urheu, M., Weinberger, P., Paternostro, R., Simbrunner, B., Semmler, G., Willheim, C., Pinter, M., Ferenci, P., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.02.012 · Cited by 19
Ghouse, J., Gellert‐Kristensen, H., O’Rourke, C. J., Seidelin, A.-S., Þorleifsson, G., Sveinbjörnsson, G., Tragante, V., Konkwo, C., Brancale, J., Vilarinho, S., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101485 · Cited by 23
Self-citationŠenkeříková, R., Fraňková, S., Jirsa, M., Kreidlová, M., Merta, D., Neřoldová, M., Chmelova, K., Špičák, J., & Šperl, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222609 · Cited by 16
“Finally, a dose dependent effect of PNPLA3 G allele on the serum ALT activity has recently been described in a large study which included patients with chronic liver disease of various aetiologies [39].”
BackgroundA closer look at the mysterious HSD17B13
Dong, X. C. (2020) · Journal of Lipid Research · doi:10.1194/jlr.c120001160 · Cited by 15
Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis
Beaudoin, J. J., Liang, T., Tang, Q., Banini, B. A., Shah, V. H., Sanyal, A. J., Chalasani, N., & Gawrieh, S. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14581 · Cited by 13
Cespiati, A., Cinque, F., Meroni, M., Lombardi, R., Dongiovanni, P., & Fracanzani, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11020586 · Cited by 17
Cong, F., Zhu, L., Deng, L., Xue, Q., & Wang, J. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02708-4 · Cited by 18
Obesity and Metabolic Dysfunction-associated Fatty Liver Disease: Understanding the Intricate Link
Vulchi, J., Suryadevara, V., Mohan, P., Kamalanathan, S., Sahoo, J., Naik, D., & Selvarajan, S. (2023) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00043 · Cited by 22
Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model
Ma, Y., Cai, H., Smith, J. A., Chu, C.-H., Mercer, S. E., Boehm, S., McDonald, I. M., Zinker, B. A., & Cheng, D. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100514 · Cited by 16
A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry
Schwantes-An, T.-H. L., Whitfield, J. B., Aithal, G. P., Atkinson, S. R., Bataller, R. A., Botwin, G., Chalasani, N., Cordell, H. J., Daly, A. K., Darlay, R., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000431 · Cited by 22
“…both alcohol-associated and nonalcohol-associated liver diseases, using rs738409 for patatin-like phospholipase domain-containing protein 3 ( PNPLA3 ), [ 10 ] rs6834314 for hydroxysteroid 17-beta dehydrogenase 13 ( HSD17B13 ), [11] and rs10401969 for Transmembrane 6 superfamily member 2 ( TM6SF2 ).”
Whole‐Exome Sequencing Study of Extreme Phenotypes of NAFLD
Kleinstein, S. E., Rein, M., Abdelmalek, M. F., Guy, C. D., Goldstein, D. B., Diehl, A. M., & Moylan, C. A. (2018) · Hepatology Communications · doi:10.1002/hep4.1227 · Cited by 15
“Indeed, we did not observe any association with HSD17B13, likely due to a combination of sample-size constraints and differences in investigated phenotypes, as our study focused on histological fibrosis, whereas HSD17B13 initially associated with serum alanine and aspartate aminotransferases.(10) Finally, as individua…”
BackgroundResultSaydmohammed, M., Jha, A., Mahajan, V., Gavlock, D. C., Shun, T. Y., DeBiasio, R., Lefever, D. E., Li, X., Reese, C. E., Kershaw, E. E., et al. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211009228 · Cited by 20
“It is well known that subsets of the overall population of patients with NAFLD/MAFLD carry specific gene variants that enhance or reduce disease risk, as demonstrated by association studies.(49) For instance, the PNPLA3 I148M variant carriers evaluated by non-invasive imaging and gene expression methods showed lower d…”
BackgroundMetabolic Associated Fatty Liver Disease in Children—From Atomistic to Holistic
Mărginean, C. O., Meliţ, L. E., & Săsăran, M. O. (2021) · Biomedicines · doi:10.3390/biomedicines9121866 · Cited by 18
Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities
Du, X., DeForest, N., & Majithia, A. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.777075 · Cited by 19
“performed an EWAS for ALT and AST levels using WES (n=46,544) and validated their associations in two additional cohorts (n=9,883) and liver biopsy samples (n=2,391) (80).”
BackgroundMethodInfluentialAdvances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
Riccio, S., Melone, R., Vitulano, C., Guida, P., Maddaluno, I., Guarino, S., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i3.221 · Cited by 16
Sakai, N., Kamimura, K., Miyamoto, H., Ko, M., Nagoya, T., Setsu, T., Sakamaki, A., Yokoo, T., Kamimura, H., Soki, H., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01929-w · Cited by 17
“ALT Alanine aminotransferase Acta2 Actin alpha 2, a-smooth muscle actin AI Aromatase inhibitor AST Aspartate aminotransferase BW Body weight CCl4 Carbon tetrachloride COL1A1 Collagen type I alpha 1 CTGF Connective tissue growth factor CYP26A1 Cytochrome P450 26A1 H&E Hematoxylin and eosin HSC Hepatic stellate cell HSD…”
BackgroundInfluentialHuman and molecular genetics shed lights on fatty liver disease and diabetes conundrum
Tavaglione, F., Targher, G., Valenti, L. V. C., & Romeo, S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.179 · Cited by 16
Seko, Y., Yamaguchi, K., Tochiki, N., Yano, K., Takahashi, A., Okishio, S., Kataoka, S., Okuda, K., Umemura, A., Moriguchi, M., et al. (2021) · Genes · doi:10.3390/genes12050628 · Cited by 16
“reported that a splice variant (rs72613567) of the 17-β-hydroxysteroid dehydrogenase 13 gene (HSD17B13) has a protective effect on the development of chronic liver disease [13].”
BackgroundWernberg, C. W., Ravnskjær, K., Lauridsen, M. M., & Thiele, M. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050930 · Cited by 15
“Since GWAS study associations, they may inform NAFLD patient assessment and stratification HSD17B13 [TA] (hydroxysteroid 17-beta dehydrogenase 13) encodes a hepatic lipid droplet protein and is associated with a protective effect against cirrhosis in fatty liver diseases due to NAFLD or alcohol [53].”
BackgroundVoilquin, L., Liu, T., Jung, Y., Taylor, N. P., Zhao, M., Charville, G. W., Nissen, S. B., Yki‐Järvinen, H., Altman, R. B., & Svensson, K. J. (2022) · iScience · doi:10.1016/j.isci.2022.105802 · Cited by 16
“Several genes have been identified as risk factors for elevated hepatic lipid accumulation, including a single-nucleotide polymorphism in the PNPLA3 gene, generating a PNPLA3-I148M variant that increases the risk of developing fatty liver disease and an HSD17B13 variant that is protective.(7,8) In addition to genetic…”
BackgroundLuukkonen, P. K., Färkkilä, M. A., Jula, A., Salomaa, V. V., Männistö, S., Lundqvist, A., Perola, M., & Åberg, F. O. (2023) · Liver International · doi:10.1111/liv.15554 · Cited by 16
Innes, H. A., Morgan, M. Y., Hampe, J., Stickel, F., & Buch, S. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17638 · Cited by 15
“Previous studies have shown unequivocally that rs72613567:TA in HSD17B13 protects against the development of cirrhosis, HCC and liver mortality 7– 9, 27 , 28 — Valenti and colleagues reported that carriage of the rs738409:G allele ( PNPLA3 ) was associated with inferior survival following HCC…”
ResultAspirin is associated with a reduced incidence of liver disease in men
Vell, M. S., Krishnan, A., Wangensteen, K. J., Serper, M., Seeling, K. S., Hehl, L., Rendel, M. D., Zandvakili, I., Vujković, M., Scorletti, E., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000268 · Cited by 14
“Interestingly, sensitivity analyses showed that carriers of protective gene variants (both HSD17B13 rs72613567[25] and mitochondrial amidoxime reducing component 1 rs2642438[26] allele carriers) benefited from additional aspirin intake.”
BackgroundSelf-citationAlcober-Boquet, L., Kraus, N., Huber, L. S., Vutukuri, R., Fuhrmann, D. C., Stroß, C., Schaefer, L., Scholich, K., Zeuzem, S., Piiper, A., et al. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00413.2023 · Cited by 18
Wang, J., Chen, X.-Y., Zhang, Y., Shen, Y., Zhu, M.-L., Zhang, J., & Zhang, J. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1562848 · Cited by 20
Semmler, G., Balcar, L., Oberkofler, H., Zandanell, S., Straßer, M., Niederseer, D., Feldman, A., Stickel, F., Strnad, P., Datz, C., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030165 · Cited by 16
“Surprisingly, this association was independent of PNPLA3, TM6SF2 (Transmembrane 6 superfamily 2 rs58542926) and MBOAT7 (membrane-bound O-acyltransferase domain-containing protein 7 rs641738), and the association with the development of NAFLD/ALD cirrhosis was stronger than that of other risk variants (including PNPLA3…”
BackgroundMortality in Patients With Genetic and Environmental Risk of Liver Disease
Schneider, C. V., Fromme, M., Schneider, K. M., Bruns, T., & Strnad, P. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001326 · Cited by 14
“, HSD17B13 rs72613567 (4,7) MTARC1 rs262438 (8)) risk of life-threatening liver diseases.”
Mychaleckyj, J. C., Valo, E., Ichimura, T., Ahluwalia, T. S., Dina, C., Miller, R. G., Shabalin, I. G., Gyorgy, B., Cao, J., Önengüt-Gümüşcü, S., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101457 · Cited by 14
“Finally, our findings are strikingly similar to another member of this gene family, HSD17B13, which encodes an analogous enzyme and was very recently discovered to play a role in liver metabolism, in which a loss-of-function gene variant protects against chronic liver disease and fibrosis, yet whose active substrate i…”
ResultGCKIII kinases in lipotoxicity: Roles in NAFLD and beyond
Mahlapuu, M., Caputo, M., Xia, Y., & Cansby, E. (2022) · Hepatology Communications · doi:10.1002/hep4.2013 · Cited by 17
“Among genetic variants that confer susceptibility to NAFLD/NASH, the best characterized are a singlenucleotide polymorphism (rs738409) in the PNPLA3 (patatin- like phospholipase domain containing 3) gene and a splice variant (rs72613567:TA) in the HSD17B13 gene,[8,9] both of which encode proteins anchored to the intra…”
BackgroundXia, Y., Andersson, E., Anand, S. K., Cansby, E., Caputo, M., Kumari, S., Porosk, R., Kilk, K., Nair, S., Marschall, H., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000037 · Cited by 15
“…the best-characterized genetic risk factors controlling the susceptibility of NAFLD — PNPLA3 and HSD17B13 — both encode proteins anchored to the hepatic LDs. [5,6] 16] Consequently, hepatic LD-associated proteins have emerged as potential targets for combating NAFLD and related metabolic disorders.”
Human genetics of HCV infection phenotypes in the era of direct-acting antivirals
Nahon, P., & Cobat, A. (2020) · Human Genetics · doi:10.1007/s00439-020-02136-4 · Cited by 17
HSD17B13 as a promising therapeutic target against chronic liver disease
Stender, S., & Romeo, S. (2020) · Liver International · doi:10.1111/liv.14411 · Cited by 16
Self-citationAssessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events
Saki, S., Saki, N., Poustchi, H., & Malekzadeh, R. (2020) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2020.166 · Cited by 17
Liu, W., Eslam, M., Zheng, K. I., Ma, H., Rios, R. S., Lv, M., Li, G., Tang, L., Zhu, P., Wang, X., et al. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00151 · Cited by 14
Acute alcohol‐associated hepatitis: Latest findings in non‐invasive biomarkers and treatment
Yamazaki, T., & Schnabl, B. (2023) · Liver International · doi:10.1111/liv.15608 · Cited by 15
Gellert‐Kristensen, H., Bojesen, S. E., Hansen, A. T., & Stender, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000608 · Cited by 15
“[20] 23] We combined the three variants into an unweighted genetic risk score as described.”
MethodSelf-citationXu, M., Chen, Z., Li, Y., Li, Y., Ge, G., Dai, R.-Z., Ni, N., Tao, J., Wang, H., Chen, Q., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00288-x · Cited by 15
“4A), emerged as a key candidate (Abul-Husn et al, 2018; Ma et al, 2019; Ma et al, 2020; Su et al, 2014; Wang et al, 2022).”
The Intestinal Thread of Fate: How the Microbiota Shapes the Story of Liver Disease
Acierno, C., Nevola, R., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Caturano, A. (2025) · Livers · doi:10.3390/livers5020017 · Cited by 16
Enomoto, H., Aizawa, N., Hasegawa, K., Ikeda, N., Sakai, Y., Yoh, K., Takata, R., Yuri, Y., Kishino, K., Shimono, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093089 · Cited by 13
Barbieri, E., Santoro, N., & Umano, G. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1062341 · Cited by 14
Alonso‐Peña, M., Barrio, M. D., Peleteiro‐Vigil, A., Jiménez-González, C., Santos‐Laso, Á., Arias, M., Iruzubieta, P., & Crespo, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310718 · Cited by 19
“These results allow researchers to conclude that the truncated protein has a protective role against liver diseases [95].”
BackgroundBuch, S., Sharma, A., Ryan, E. M., Datz, C., Griffiths, W. J., Way, M. J., Buckley, T. M. W., Ryan, J. D., Stewart, S. F., Wright, C., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16252 · Cited by 15
“Likewise, there was no significant association with HSD17B13: rs72613567, which confers protection against the development of NAFLD-related and alcohol-related cirrhosis and the subsequent development of HCC.(27,28) However, the study may also be underpowered to detect a significant modulating effect in HH.”
BackgroundResultGao, F., Zheng, K. I., Chen, S., Lee, D. H., Wu, X.-X., Wang, X.-D., Targher, G., Byrne, C. D., Chen, Y.-P., Kim, W. K., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000321 · Cited by 17
La Estoria de España de Alfonso X: creación y evolución
Catalán, D. (1992) · Cited by 86
Butcko, A. J., Putman, A. K., & Mottillo, E. P. (2024) · Antioxidants · doi:10.3390/antiox13010087 · Cited by 13
Co-immunoprecipitation for identifying protein–protein interaction on lipid droplets
Fu, X., Zhang, S., & Liu, P. (2024) · Biophysics Reports · doi:10.52601/bpr.2024.240007 · Cited by 12
“Overexpression of LD protein HSD17B13 has been associated with hepatic steatosis (Abul-Husn et al. 2018; Su et al. 2014).”
BackgroundHSD17B13 liquid–liquid phase separation promotes leukocyte adhesion in chronic liver inflammation
Ye, J., Huang, X., Yuan, M., Wang, J., Jia, R., Wang, T., Tan, Y., Zhu, S. N., Xu, Q., & Wu, X. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae018 · Cited by 12
Hou, W., Watson, C., Cecconie, T., Bolaki, M. N., Brady Jennifer, J., Lu, Q., Gatto, G. J. J., & Day, T. A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107353 · Cited by 11
Mahmood, S., Morrice, N., Thompson, D., Milanizadeh, S., Wilson, S., Whitfield, P. D., Mcilroy, G. D., Rochford, J. J., & Mody, N. (2025) · Experimental Physiology · doi:10.1113/ep092535 · Cited by 15
“Moreover,severalgenevariantsof HSD17B13 linked to MASLD/MASH have been identified by GWAS performed in cohorts around the world (Amangurbanova et al., 2023).”
InfluentialResection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
Campani, C., Bensi, C., Milani, S., Galli, A., & Tarocchi, M. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s252506 · Cited by 14
NAFLD and renal function in children: is there a genetic link?
Sessa, A. D., Guarino, S., Passaro, A. P., Liguori, L., Umano, G. R., Cirillo, G., del Giudice, E. M., & Marzuillo, P. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1906649 · Cited by 13
Mao, Y., Du, J., Li, B., Wang, J., Xuan, S., Yang, S., Tang, Z., & Wang, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330504 · Cited by 15
Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population
Elmansoury, N., Megahed, A. A., Kamal, A., El-Nikhely, N. A., Labane, M., Abdelmageed, M., Daly, A. K., & Wahid, A. M. (2024) · Genes · doi:10.3390/genes15040455 · Cited by 14
“Abul-Husn NS et al. [38] reported a protective effect of HSD17B13 rs9992651 G>A against fibrosis but essentially none against milder steatosis.”
BackgroundYang, H., Ou, F., Chang, Q., Jiang, J., Liu, Y., Ji, C., Chen, L., Xia, Y., & Zhao, Y. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13506 · Cited by 17
Self-citationAlcohol-associated liver disease: Emerging therapeutic strategies
Mullish, B. H., & Thursz, M. R. (2024) · Hepatology · doi:10.1097/hep.0000000000000986 · Cited by 14
“[100] N-acetyl-galactosamine conjugation allows small interfering RNA molecules to be targeted to hepatocytes.”
Hermanson, J. B., Tolba, S. A., Chrisler, E. A., & Leone, V. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109704 · Cited by 14
Zhang, J., Liu, X., Jin, X. J., Mao, X., Xu, X., Zhang, X., Shang, K., Xu, Y., Zhang, Y., Meng, G., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107664 · Cited by 11
Xue, H., Wang, L., Sun, D., Wu, Y., Yu, C., Huang, Y., Chan, S. O., Ling, W., Lv, J., Li, L., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.021 · Cited by 15
Bhattacharya, I., Maity, D. K., Kumar, A., Sarkar, S., Bhattacharya, T., Sahu, A., Sreedhar, R., & Arumugam, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04257-x · Cited by 13
“Loss-of-function mutation of HSD17B13 has been shown to progress MAFLD, demonstrating its disease-protective effect (Abul-Husn et al. 2018; Amangurbanova et al. 2023).”
Genetic and Environmental Susceptibility to Alcoholic Hepatitis
Morgan, M. Y., Sharma, M., & Atkinson, S. R. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.04.001 · Cited by 11
Gil‐Gómez, A., Rojas, Á., García-Lozano, M. D. R., Múñoz‐Hernández, R., Gallego‐Durán, R., Maya‐Miles, D., Montero‐Vallejo, R., Gato, S., Gallego, J., Francés, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911840 · Cited by 13
“Recently, an indel variant (T > TA variant, rs72613567) in the 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) gene, leading to the production of a truncated protein with reduced activity, has been associated with decreased aminotransferase levels and a reduction of liver injury in the setting of a fatty liver, mit…”
BackgroundSookoian, S. C., Arrese, M. A., & Pirola, C. J. (2018) · Hepatology · doi:10.1002/hep.30209 · Cited by 11
“Abul-Husn et al. found a significant interaction between the implicated rs72613567:-/A allele and the risk rs738409 G allele,(4) which directly impacted on liver PNPLA3 mRNA levels (Fig.”
BackgroundMethodResultInfluentialWang, J., Zheng, J., Ren, X., Wang, S., Wang, G., Hu, B., Yang, H., & Liu, H. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13120 · Cited by 12
Dhindsa, R. S., Burren, O. S., Sun, B. B., Prins, B. P., Matelska, D., Wheeler, E., Mitchell, J., Oerton, E., Hristova, V. A., Smith, K. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.09.511476 · Cited by 11
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
Fraser, D. A., Harrison, S. A., & Schuppan, D. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159804 · Cited by 11
“Although the role of specific AA metabolites in the pathogenesis of NASH is beyond the scope of the current review, multiple lines of evidence supporting a role for the AA cascade in the pathogenesis of NASH [61–63], including the identification of AA metabolites, such as hydroxyeicosatetraenoic acids (HETEs) (that ar…”
BackgroundFaccioli, L. A. P., Cetin, Z., Kocas‐Kilicarslan, Z. N., Ortiz, K., Sun, Y., Hu, Z., Kurihara, T., Tafaleng, E. N., Florentino, R. M., Wang, Z., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713406 · Cited by 11
Self-citationGermline Genetic Associations for Hepatobiliary Cancers
Chotiprasidhi, P., Sato-Espinoza, A. K., & Wangensteen, K. J. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.12.010 · Cited by 12
Wu, H., Li, S., Chen, L., Yang, X., & Tan, X. W. (2024) · Food & Function · doi:10.1039/d3fo04602h · Cited by 11
Qin, S., Cheng, X., Zhang, S., Shen, Q., Zhong, R., Chen, X., & Yi, Z. (2024) · Hepatology International · doi:10.1007/s12072-024-10665-7 · Cited by 15
“Genome-wide association studies have ascertained that PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 were not only solidly linked to fatty liver disease [9–11]but also associated with decompensated cirrhosis, fibrosis stage F4 (cirrhosis) or NAFLD fibrosis score [2].”
Self-citationCurrent Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases
Durazzo, M., Ferro, A., Navarro‐Tableros, V., Gaido, A., Fornengo, P., Altruda, F., Romagnoli, R., Moestrup, S. K., Calvo, P. L., & Fagoonee, S. (2025) · Biomolecules · doi:10.3390/biom15010121 · Cited by 11
Chen, L., Liang, Z., Mao, J., Liao, Z., Liu, Y., Ou, D., Liu, C., & Li, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00119 · Cited by 10
Self-citationDeep Learning Reveals Liver MRI Features Associated With PNPLA3 I148M in Steatotic Liver Disease
Chen, Y., Laevens, B. P. M., Lemainque, T., Müller‐Franzes, G. A., Seibel, T., Dlugosch, C., Clusmann, J., Koop, P., Gong, R., Liu, Y., et al. (2025) · Liver International · doi:10.1111/liv.70164 · Cited by 11
“For example, the presence of SNPs HSD17B13 rs72613567_T and MTARC1 rs2642438_A reduces the risk of developing conditions such as liver cirrhosis and HCC [10–13].”
Self-citationMAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk
Mostafa, A. M., Pan, Z., Yu, M., Örmecı, N., Fouad, Y. M., & Eslam, M. (2025) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s506402 · Cited by 21
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.